Company news

Viking Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

October 8, 2024

Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

July 23, 2024

Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024

July 16, 2024

Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association

June 23, 2024

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

June 3, 2024

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

April 23, 2024

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

April 16, 2024

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

March 25, 2024

Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

March 3, 2024

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

February 27, 2024

Viking Therapeutics Announces Proposed Public Offering of Common Stock

February 26, 2024

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

February 26, 2024

Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

February 6, 2024

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024

January 30, 2024

Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

November 12, 2023

Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 24, 2023

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

October 22, 2023

Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023

October 17, 2023

Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

October 16, 2023

Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

October 9, 2023

Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

September 5, 2023

Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 25, 2023

Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023

July 18, 2023

Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

May 15, 2023

Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 25, 2023

Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023

April 19, 2023

Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference

April 10, 2023

Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters' Option to Purchase Additional Shares

April 2, 2023

Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

March 28, 2023

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735

March 27, 2023

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

March 27, 2023

Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

February 7, 2023

Viking Therapeutics to Present at SVB Securities Global Biopharma Conference

February 6, 2023

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023

January 31, 2023

Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

January 8, 2023

Viking Therapeutics to Present at Stifel 2022 Healthcare Conference

November 7, 2022

Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 25, 2022

Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022

October 17, 2022

Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022

August 1, 2022

Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 26, 2022

Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022

July 19, 2022

Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

July 18, 2022

Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022

July 5, 2022

Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 15, 2022

Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

April 26, 2022

Viking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022

April 19, 2022

Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

April 5, 2022

Viking Therapeutics to Present at Upcoming Investor Conferences

March 7, 2022

Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

February 8, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.